89Zr-DFO-Atezolizumab

N/A

Report date: 2025/11/25 15:53:49

Base Information

Drug Name89Zr-DFO-Atezolizumab

Drug Alias Name89Zr-DFO-Atezolizumab

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Zirconium > 89Zr +[4]

Mechanisms of ActionPositron-emission tomography enhancersProgrammed death-ligand 1 blockers

TargetsProgrammed death-ligand 1

Therapy Area/IndicationsDiagnostic agentsCarcinoma, Renal CellLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity of Texas Southwestern Medical Center

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Medical Center Groningen

Inactive CompaniesN/A

Active IndicationsDiagnostic agentsCarcinoma, Renal CellLymphoma, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A